Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to evaluate the antitumor activity and confirm the safety for the
combination of Fibroblast Growth Factor Receptor (FGFR) inhibitor futibatinib and
anti-programmed cell death-1 (PD-1) antibody pembrolizumab in patients with advanced or
metastatic urothelial cancer who are not candidates to receive a platinum-based treatment
regimens.